Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy (original) (raw)
Related papers
Adverse Drug Reactions and its Management Associated with Cancer Chemotherapy
International Journal of Research in Pharmaceutical Sciences, 2020
Adverse Drug Reactions () are the problem that adds extra burden in the global scenario. Anticancer drugs can lead to severe negative consequences due to these . This study was conducted to assess the causality, severity and preventability of the identified of chemotherapeutic drugs among hospitalized patients diagnosed with cancer and also to analyze its management. A prospective observational study was conducted among cancer patients for a period of eight months. A total of 120 hospitalized patients who developed at least one ADR due to chemotherapy were included in this study. Data were collected and documented in a well-designed data collection form. A total of 166 were detected in 120 patients. 33(19.8%), was found as the most commonly identified ADR. Patients administered with as were found to be reported with the highest number of (36). According to Naranjo’s scale and WHO causality assessment, 110(66.2%) and 105(63.2%) were found probable. & scale of severity showed that 97(...
Experimental and Therapeutic Medicine, 2022
A descriptive and cross-sectional study was performed to characterize the degree of immediate adverse reaction and the type of causative antineoplastic drug presented by 371 different patients treated for cancer at the oncology day hospital unit of the San Carlos Clinical Hospital (Madrid, Spain), during the period between January 2015 and December 2019. In the case series, 488 immediate adverse reactions secondary to chemotherapy toxicity were detected. The dominating factors were: Female sex, age from 51-70 years old, skin melanoma and the use of vinca alkaloids and analogs. Among the most frequent adverse reactions, the following stood out: Disorders of the nervous and musculoskeletal systems and of the connective tissue. There was a higher number of moderate adverse reactions (grade 2 according to the Common Terminology Criteria for Adverse Events Version 4.0) between the first and third chemotherapy cycles, with a latency period of between 6 and 15 min., generally lasting less than 30 min. Association with the degree of immediate adverse reaction (grade) has been observed in male subjects over 71 years of age, with soft tissue neoplasm type and monoclonal antibodies therapeutic group.
The study is the assessment of Adverse drug reaction in a Cancer Care Center. We have conducted the prospective study to analyse the ADR The study population consisted of 178 patients in total. Among them 59% (n=105) of the patients were females. On classifying the patients based on age 33.15% (n=59) of the patients were of age group 60-69. From the total prescription 37.64% (n=67) of the diagnosis was concerned with the reproductive system and in 28.65% (n=51) of the cases the site of tumor was the cervix. As a part of the chemotherapy the patients were prescribed with various classes of anti-cancerous agents. About 67.97% (n=121) alkylating agents were preferred. And most frequently used anti-cancer drug was 5-FU. In 23.59% (n=42) of patients with a combination cisplatin + 5-FU was prescribed. 34.83% (n= 62) of patients had been prescribed with quinolones and 19.66% (n=35) of cases were given with ofloxacin. The prescriptions contained drugs other than anti-cancer agents like nutritional supplements. 35.39% (n=63) of the prescriptions were prescribed with Iron supplements. On classifying the ADRs found according to Wills & Brown classification of ADR assessment, 45.89% of the ADRs were of Type A(Augmented reaction) the chemotherapeutic drugs have a narrow therapeutic index and the dosage needed to achieve a therapeutic response usually proves toxic to the body’s rapidly proliferating cells. Early modifications in dosage regimen of chemotherapeutic agents may minimize the hazardous ADRs. Through pharmacist intervention in the adjustment of dosage regimen and supportive care maximum benefits can be gained by the patients because supportive care improves patient comfort and improves quality of life. Keywords: ADR, Pharmacist Intervention, Supportive care.
Seminars in Thrombosis and Hemostasis, 2007
Objective: The aim of the study was to document the frequency, severity, evolution, and impact of adverse events (AE) on chemotherapy and the clinical evolution of patients with hematologic malignancies. Material and Methods: A prospective study was carried out at a hematology reference center in Northeastern Mexico over 1 year. All patients with malignant disease developing adverse chemotherapy events were included in the study. AEs were classified according to Common Terminology Criteria for AEs v5.0. Results: One-hundred and seventy-four patients attended the hematology clinic for outpatient chemotherapy. Acute lymphoblastic leukemia accounted for 51.7%, non-Hodgkin's lymphoma 25.9%, acute myeloid leukemia 9.8%, multiple myeloma 6.3%, Hodgkin's lymphoma 5.7%, and chronic myeloid leukemia 0.6% of the cases. A total of 191 AEs, including 79 hospital admissions, were registered in 58 (33.3%) patients. About 62.3% of the cases were Grade 3, in 43.9% of the events complete resolution was achieved, whereas the chemotherapy regimen had to be suspended in 13.6% of the cases. Febrile neutropenia was the main AE, documented in 77.6%; four (6.9%) patients died as a direct consequence of this complication. Thrombocytopenia occurred in 65.5% and anemia in 55.2%, with no deaths. Conclusions: AEs secondary to chemotherapeutic drugs used in the treatment of hematological malignancies constitute an important cause of morbidity and occasional mortality and should be closely monitored and documented.
Complications of systemic anti-cancer treatment
Medicine, 2020
Systemic anti-cancer treatment (SACT) is a broad term, including both conventional chemotherapy agents and biological agents such as immunotherapy. The diversity of SACT now available has resulted in a wide profile of toxicities, some of which, such as neutropenic sepsis and severe colitis, can be life-threatening. In particular, immunotherapy-related adverse events require specific management with immunosuppression in moderate to severe cases. Prompt identification and management of acute toxicities, and early medical input, is essential to reduce morbidity and mortality. Diagnosis of toxicity secondary to SACT should be shared with the patient's oncology team so that appropriate amendments to oncology treatment regimens can be considered before the patient is given their next cycle of SACT.
REVIEW ARTICLE ON CLINICAL ADVERSE DRUG REACTION OF ANTI-NEOPLASTIC AGENTS
Journal of Medical Pharmaceutical And Allied Sciences www.jmpas.com ISSN NO. 2320 - 7418. Journal of medical Pharmaceutical and allied sciences, V 7 - I 2, 755, 2018, 1000-1007 Article 1523793728 jmpas march, 2018
Adverse drug reaction (ADR) is an unintended and unexpected effect can be caused by many drugs; this definition is differing by the side effect. It is fourth leading cause of death in developed western countries and sixth leading cause of death in the world. An adverse drug reaction (ADRs) shows an important public health problem in animals, human beings and the environment which include less efficacy of drug, sensitivity like reactions. Pharmacovigilance is associated in the field of ADRs study. At present Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer uncontrolled growth of cells is called cancer. Cancer cells are also referred to as tumors or neoplasms. It is a heterogeneous group of diseases caused by the impairment of normal functioning of genes, which leads to genetic damage. Many treatment options for cancer exist with the primary ones including surgery, chemotherapy, radiation therapy and palliative care. These treatments are used depending upon the type, location and grade of the cancer. The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the mouth, stomach, and intestines. Along with other oncology clinicians, intervention played by Clinical Pharmacist is vital and can therapeutically minimize, assess, monitor and manage ADRs of ANAs. Clinical Pharmacist should inform the clinicians about these adverse reactions during each administration time